Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

• Status: Withdrawn
• Trial end date: 2017-09-01

Summary

In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD is a combination of cyclophosphamide, mesna, vincristine (vincristine sulfate), doxorubicin (doxorubicin hydrochloride), dexamethasone, methotrexate, cytarabine, and rituximab (only for patients with cluster of differentiation [CD]20 positive disease). Researchers don't know all the ways that this drug may affect people

• Phase: Phase 2

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Leucovorin; Levoleucovorin; Liposomal doxorubicin; Mesna; Methotrexate; Prednisone; Rituximab; Vincristine